Amcor Q2 EPS Tops Estimates, Clinical Trial Packaging Market to Reach $2.7B by 2035
Amcor posted Q2 fiscal 2026 adjusted EPS of $0.86, $0.03 above consensus, while revenues of $5.45B rose 68% Y/Y but trailed estimates. The U.S. clinical trial packaging market will grow from $1.05B in 2025 to $2.7B by 2035 at a 9.9% CAGR, driven by biopharma R&D, smart packaging, sustainability solutions.
1. Q2 Fiscal 2026 Performance
Amcor reported adjusted EPS of $0.86 for Q2 fiscal 2026, beating consensus by $0.03. Revenue rose 68% year-over-year to $5.45 billion, driven by gains from the Berry acquisition, but fell short of analyst projections, reflecting persistent volume declines across key segments.
2. U.S. Clinical Trial Packaging Market Outlook
The U.S. clinical trial packaging market is projected to expand from $1.05 billion in 2025 to $2.7 billion by 2035 at a 9.9% CAGR. Growth is fueled by increased biopharma R&D investments, adoption of smart packaging technologies, sustainability initiatives and advanced serialization methods, presenting long-term opportunities for packaging providers.